Browse 122 retinitis pigmentosa clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.
Retinitis pigmentosa usually begins with trouble seeing at night and slowly narrows side vision, and more than 100 genes have been linked to it. The eye was the site of a medical first: in 2017 the FDA approved its first gene therapy for an inherited disease, for vision loss caused by one of those genes. Most people with retinitis pigmentosa have a different gene change and still no approved treatment. Gene therapies, cell therapies, and treatments that work regardless of the gene are now in trials, and genetic testing is the first step toward them.
Sponsor: National Institute of Environmental Health Sciences (NIEHS)
Sex: All
Age: 0 - 70+
Code: NCT01500447
Recruiting
Natural History Study of Patients with HPDL Mutations
for
Mitochondrial Encephalomyopathies,
Location: San Diego CA
Sponsor: University of California, San Diego
Sex: All
Age: 0+
Code: NCT05848271
Recruiting
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
for
Leber Congenital Amaurosis 10, Blindness,
Location: Philadelphia PA, Miami FL, Toronto, Iowa City IA,
Sponsor: Laboratoires Thea
Sex: All
Age: 6+
Code: NCT06891443
Phase 3, Recruiting
New
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
for
Muscular Dystrophies,
Location: London
Sponsor: Avidity Biosciences, Inc.
Sex: Male
Age: 7 - 16
Code: NCT07587242
Phase 3, Recruiting
Evaluating AI-Generated Plain Language Summaries on Patient Comprehension of Ophthalmology Notes Among English-Speaking Patients